Trial Profile
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Lasofoxifene (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ELAINE; ELAINE 1
- Sponsors Sermonix Pharmaceuticals
- 16 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 Dec 2024.
- 16 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Dec 2024.
- 14 Dec 2023 Lithuania and Czechia were the planned locations as per European Clinical Trials Database.